|
|
|
Volumn 21, Issue 131, 2012, Pages 233-
|
|
Vandetanib: Too dangerous in medullary thyroid cancer
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DACARBAZINE;
DOXORUBICIN;
LEVOTHYROXINE;
PLACEBO;
PROTEIN TYROSINE KINASE INHIBITOR;
VANDETANIB;
ARTICLE;
BLEEDING;
CANCER CHEMOTHERAPY;
CARDIOVASCULAR DISEASE;
DIARRHEA;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG FATALITY;
DRUG SAFETY;
EUROPEAN UNION;
GASTROINTESTINAL DISEASE;
HUMAN;
METABOLIC DISORDER;
NEUROTOXICITY;
OVERALL SURVIVAL;
PROGRESSION FREE SURVIVAL;
QT PROLONGATION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SIDE EFFECT;
SKIN TOXICITY;
SUDDEN DEATH;
TABLET;
THYROID CANCER;
THYROID MEDULLARY CARCINOMA;
TORSADE DES POINTES;
TREATMENT OUTCOME;
VISUAL DISORDER;
ANTINEOPLASTIC AGENTS;
EVIDENCE-BASED MEDICINE;
HUMANS;
PATIENT SAFETY;
PIPERIDINES;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
RISK FACTORS;
THYROID NEOPLASMS;
TREATMENT OUTCOME;
|
|
EID: 84872491531
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (3)
|
